Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
Vida TerzićJoe Miantezila BasiluaNicolas BillardLucie de GastinesDrifa BelhadiClaire Fougerou-LeurentNathan Peiffer SmadjaNoémie MercierChristelle DelmasAssia FerraneAline DechanetJulien PoissyHélène EspérouFlorence AderMaya HitesClaire AndrejakRichard GreilJosé-Artur PaivaThérèse StaubEvelina TacconelliCharles BurdetDominique CostagliolaFrance MentréYazdan YazdanpanahAlpha Diallonull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Remdesivir treatment was not associated with an increased risk of cardiac AEs compared with control in patients hospitalized with moderate or severe COVID-19. These results are consistent with other randomized, controlled trials and meta-analyses. Clinical Trials Registration. NCT04315948; EudraCT 2020-000936-23.
Keyphrases
- clinical trial
- meta analyses
- phase iii
- phase ii
- randomized controlled trial
- end stage renal disease
- systematic review
- coronavirus disease
- ejection fraction
- open label
- sars cov
- left ventricular
- newly diagnosed
- double blind
- chronic kidney disease
- study protocol
- small molecule
- peritoneal dialysis
- prognostic factors
- high intensity
- high throughput
- single cell